By Category
in this category 678 findings drawn from 570 published documents. The most recent cases are below; the full set is in search.
See all Contamination control findingsBeta-lactam drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.
View official sourceMicrobial contamination was present in the.
View official sourceContamination was observed in your production area and areas adjacent to production areas.
See every finding in this document View official sourceThe separate or defined areas and control systems necessary to prevent contamination or mix-ups are deficient.
See every finding in this document View official sourceProcedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established, written and followed.
See every finding in this document View official sourceAppropriate written procedures, designed to prevent objectionable microorganisms in drug products not required to be sterile, shall be established and followed.
See every finding in this document View official sourceThese findings are a record of the moment each document was published. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out — do not read them as the current state; check the regulator's official announcements for the latest status. Counts are measured from public data as of 2026-09-04, and findings are extracted automatically from the regulator's published documents. “View official source” on each case links directly to that document.
Growth stages previewSolve a quiz to start hatching
Your growth record is stored safely in this browser.
